At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis receiving the investigational IL-13 inhibitor lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced April 11 at the 4th Annual Revolutionizing Atopic Dermatitis Conference.
Clinical-stage biopharmaceutical company SAB Biotherapeutics announced an update to the design of the ongoing Phase 3 ACTIV-2 trial evaluating the clinical efficacy and safety of SAB-185 for the treatment of participants with mild-moderate COVID infections at higher risk for progression to hospitalization.
According to a recent study conducted by researchers at Harvard Medical School and Beth Israel Deaconess Medical Center, 76 percent of the adverse side effects (such as fatigue or headache) that people experienced after receiving their first COVID-19 vaccination were also reported by participants who received a placebo shot.
AB Science announced the publication of long-term follow-up data showing that the company’s lead compound, masitinib, extended survival in Amyotrophic Lateral Sclerosis (ALS) patients by 25 months compared to placebo when treatment was started early.
AbbVie’s Rinvoq (upadacitinib) hit the mark as a maintenance drug for ulcerative colitis in a Phase III study. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.
Sage Therapeutics’ experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.
Placebo response is one of the most significant challenges faced by drug developers who are investigating new pain medications. According to a review of published chronic neuropathic pain trials, placebo responses have increased in magnitude over time, making it even more difficult to definitively demonstrate treatment advantage. Research has also shown that up to 60 percent of study participants may experience placebo-related analgesic responses and that these responses may be persistent.
The U.S. Food and Drug Administration granted vTv Therapeutics’ TTP399 Breakthrough Therapy designation for type 1 diabetes.
Novavax Inc. said on April 5 participants in the company’s Covid-19 vaccine trials in South Africa and the UK can receive additional shots, ensuring those who received a placebo can also get the active vaccine.
Emergent BioSolutions’ Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19 showed that the addition of the treatment to Gilead Sciences’ remdesivir did not provide clinical benefit compared to standard of care plus placebo in hospitalized adult COVID-19 patients with symptoms for less than 12 days.